Analysts See Daiichi Sankyo Exercising Light Control Over Ranbaxy
This article was originally published in The Pink Sheet Daily
Executive Summary
Parallels to Novartis-Sandoz 2005 combination seen.
You may also be interested in...
Ranbaxy Management Would Likely Rebuf Any Pfizer Offer – Analysts
"It's hard to see how Pfizer would run the company," one analyst said in an interview.
Japan’s Daiichi Sankyo In “Transformational” Deal to Buy Majority Stake In India’s Ranbaxy Labs
Daiichi will pay $4.6 billion for stake in generics marketer.
Ranbaxy Could See Six-Year Earnings Surge With Recent Collaborations
Firm signs antibacterial, antifungal drug development deal with Merck with $100 million-plus potential for each target.